Milestone Pharmaceuticals is expected to report a Q2 2026 loss of $0.18 per share on revenue of $1.85 million, with the current $2.45 stock price trading significantly below the $8.50 average analyst target. The central focus for investors this quarter is the commercial execution and prescription ramp-up of Cardamyst (etripamil) following its recent market entry for PSVT.
Analysts are specifically looking for evidence of successful payer coverage and physician adoption to validate the long-term peak sales potential of the nasal spray. Furthermore, management's update on the cash runway and the development timeline for etripamil in atrial fibrillation will be critical for determining near-term capital needs.